Silo Pharma Inc (SILO)

$0.40 +0.01 (1.54%)
Market Cap 6.34M
Revenue (ttm) 70,000.00
Net Income (ttm) -4.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,042.86%
Debt to Equity Ratio 0.00
Volume 334,700
Avg Vol 5,098,364
Day's Range N/A - N/A
Shares Out 16.27M
Stochastic %K 20%
Beta 0.65
Analysts Strong Sell
Price Target $10.00

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology
Sector: Healthcare
Phone: 718 400 9031
Address:
677 North Washington Boulevard, Sarasota, United States
BankingBig
BankingBig May. 12 at 5:02 PM
$SILO I really like this here at this price
0 · Reply
Jbjb90
Jbjb90 May. 8 at 3:19 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-files-provisional-patent-for-ibogaine-based-therapeutic-zgmsgrxu50bs.html
0 · Reply
Jbjb90
Jbjb90 May. 6 at 3:57 PM
$SILO
0 · Reply
MadMaverick
MadMaverick May. 5 at 11:00 PM
🚨 Swing Scout Strikes Again! 🚨 The results are in, and the numbers speak for themselves. While others are playing guessing games with the market, our community is locking in consistent gains. The Breakdown: $ASAN & $RPD : Both triggered auto-sells at 15%+ profit. 💰Consistent Wins: Real positions, real growth, and zero guesswork. Success in trading isn't about luck; it’s about having the right tools in your corner to cut through the noise. $SILO $FIGG
0 · Reply
Jbjb90
Jbjb90 May. 5 at 9:01 PM
$SILO has anyone heard or read any recent update on this https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-and-silo-pharma-nasdaq-silo-today-announced-the-formation-of-a-5050-joint-venture-to-develop-a-first-in-class-gdnf-based-therapy-licensed-from-the-us-department-of-veterans-affairs-the-therapy-targe-302490308.html
0 · Reply
Jbjb90
Jbjb90 May. 5 at 12:07 PM
$SILO seems to have bottomed here around .42-.45
0 · Reply
BiotechGoldenEra
BiotechGoldenEra May. 5 at 2:25 AM
$SILO looks like pumpin
0 · Reply
1bath
1bath May. 4 at 5:16 PM
$SILO The price will reach $1 in May, and after the merger in June, the price will be around $40-100. go to the future
1 · Reply
StMartinBr
StMartinBr May. 1 at 9:52 AM
$SILO loaded
0 · Reply
Jbjb90
Jbjb90 Apr. 30 at 3:11 PM
$SILO lets go
0 · Reply
Latest News on SILO
Silo Pharma files provisional patent for ibogaine-based therapeutics

2026-05-07T18:37:18.000Z - 5 days ago

Silo Pharma files provisional patent for ibogaine-based therapeutics

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

May 7, 2026, 8:05 AM EDT - 6 days ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Apr 29, 2026, 9:08 AM EDT - 13 days ago

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Silo Pharma expands into AI technology with Qwikagents asset purchase

2026-04-22T21:10:17.000Z - 20 days ago

Silo Pharma expands into AI technology with Qwikagents asset purchase

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Apr 22, 2026, 4:15 PM EDT - 20 days ago

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

2026-04-06T20:20:47.000Z - 5 weeks ago

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

Apr 6, 2026, 4:15 PM EDT - 5 weeks ago

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

Silo Pharma announces $1M share repurchase program

2026-02-23T21:38:21.000Z - 2 months ago

Silo Pharma announces $1M share repurchase program

Silo Pharma Announces Share Buyback Program

Feb 23, 2026, 4:15 PM EST - 2 months ago

Silo Pharma Announces Share Buyback Program

Silo Pharma receives Notice of Allowance in Japan for SPC-15

2026-02-18T13:35:47.000Z - 2 months ago

Silo Pharma receives Notice of Allowance in Japan for SPC-15

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Feb 18, 2026, 8:28 AM EST - 2 months ago

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15

2025-12-30T13:35:34.000Z - 4 months ago

Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Dec 30, 2025, 8:05 AM EST - 4 months ago

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Silo Pharma partners with Allucent for planned FDA IND application for SPC-15

2025-11-17T13:11:11.000Z - 6 months ago

Silo Pharma partners with Allucent for planned FDA IND application for SPC-15

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

Nov 17, 2025, 8:05 AM EST - 6 months ago

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments

2025-10-29T12:30:37.000Z - 7 months ago

Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Oct 29, 2025, 8:25 AM EDT - 7 months ago

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Silo Pharma provides update on SPC-15 advancement, digital asset program

2025-10-23T12:50:17.000Z - 7 months ago

Silo Pharma provides update on SPC-15 advancement, digital asset program

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Oct 23, 2025, 8:45 AM EDT - 7 months ago

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Silo Pharma announces initial Bitcoin purchase

2025-10-08T12:51:28.000Z - 7 months ago

Silo Pharma announces initial Bitcoin purchase

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Oct 8, 2025, 8:45 AM EDT - 7 months ago

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Silo Pharma acquires ResearchCoin crypto tokens

2025-10-06T12:36:25.000Z - 7 months ago

Silo Pharma acquires ResearchCoin crypto tokens

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Oct 6, 2025, 8:10 AM EDT - 7 months ago

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 1, 2025, 4:20 PM EDT - 7 months ago

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma prices 2.86M shares at 87.5c in registered direct offering

2025-09-30T12:35:55.000Z - 8 months ago

Silo Pharma prices 2.86M shares at 87.5c in registered direct offering

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 30, 2025, 8:02 AM EDT - 8 months ago

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma updates strategic agreement with Fireblocks

2025-09-29T18:35:25.000Z - 8 months ago

Silo Pharma updates strategic agreement with Fireblocks

Silo Pharma signs strategic agreement with Fireblocks

2025-09-23T12:40:14.000Z - 8 months ago

Silo Pharma signs strategic agreement with Fireblocks

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Sep 16, 2025, 8:11 AM EDT - 8 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Sep 9, 2025, 9:10 AM EDT - 8 months ago

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Sep 3, 2025, 8:25 AM EDT - 9 months ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 21, 2025, 2:00 PM EDT - 9 months ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 19, 2025, 8:05 AM EDT - 9 months ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Aug 5, 2025, 8:32 AM EDT - 10 months ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 16, 2025, 8:45 AM EDT - 10 months ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jul 7, 2025, 8:15 AM EDT - 11 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:38 AM EDT - 11 months ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 11 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 11, 2025, 9:00 AM EDT - 11 months ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Jun 5, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 21, 2025, 8:55 AM EDT - 1 year ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering

May 16, 2025, 4:15 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 4:07 PM EDT - 1 year ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

May 14, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 30, 2025, 8:11 AM EDT - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Apr 28, 2025, 7:50 AM EDT - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Mar 26, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 26, 2025, 1:30 PM EST - 1 year ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 18, 2025, 8:50 AM EST - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Feb 11, 2025, 7:45 AM EST - 1 year ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 22, 2025, 8:29 AM EST - 1 year ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Jan 2, 2025, 8:45 AM EST - 1 year ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Dec 18, 2024, 7:35 AM EST - 1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 29, 2024, 8:05 AM EST - 1 year ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Nov 18, 2024, 8:40 AM EST - 1 year ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Oct 31, 2024, 8:35 AM EDT - 1 year ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Sep 10, 2024, 6:35 AM EDT - 1 year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

BankingBig
BankingBig May. 12 at 5:02 PM
$SILO I really like this here at this price
0 · Reply
Jbjb90
Jbjb90 May. 8 at 3:19 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-files-provisional-patent-for-ibogaine-based-therapeutic-zgmsgrxu50bs.html
0 · Reply
Jbjb90
Jbjb90 May. 6 at 3:57 PM
$SILO
0 · Reply
MadMaverick
MadMaverick May. 5 at 11:00 PM
🚨 Swing Scout Strikes Again! 🚨 The results are in, and the numbers speak for themselves. While others are playing guessing games with the market, our community is locking in consistent gains. The Breakdown: $ASAN & $RPD : Both triggered auto-sells at 15%+ profit. 💰Consistent Wins: Real positions, real growth, and zero guesswork. Success in trading isn't about luck; it’s about having the right tools in your corner to cut through the noise. $SILO $FIGG
0 · Reply
Jbjb90
Jbjb90 May. 5 at 9:01 PM
$SILO has anyone heard or read any recent update on this https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-and-silo-pharma-nasdaq-silo-today-announced-the-formation-of-a-5050-joint-venture-to-develop-a-first-in-class-gdnf-based-therapy-licensed-from-the-us-department-of-veterans-affairs-the-therapy-targe-302490308.html
0 · Reply
Jbjb90
Jbjb90 May. 5 at 12:07 PM
$SILO seems to have bottomed here around .42-.45
0 · Reply
BiotechGoldenEra
BiotechGoldenEra May. 5 at 2:25 AM
$SILO looks like pumpin
0 · Reply
1bath
1bath May. 4 at 5:16 PM
$SILO The price will reach $1 in May, and after the merger in June, the price will be around $40-100. go to the future
1 · Reply
StMartinBr
StMartinBr May. 1 at 9:52 AM
$SILO loaded
0 · Reply
Jbjb90
Jbjb90 Apr. 30 at 3:11 PM
$SILO lets go
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 2:23 AM
$SILO
0 · Reply
StMartinBr
StMartinBr Apr. 29 at 6:29 PM
$SILO place of business not too far from my house
1 · Reply
coastalgains
coastalgains Apr. 29 at 6:03 PM
$SILO I bought this 💩. Don't be like me.
0 · Reply
prismmarketview
prismmarketview Apr. 29 at 3:27 PM
$SILO highlighting PTSD candidate SPC‑15 after Trump’s EO to fast‑track psychedelic research. SPC‑15 is an intranasal 5‑HT4 agonist for prophylactic PTSD treatment, using nose‑to‑brain delivery and a 505(b)(2) regulatory path. Info only, not investment advice. #SILO #PTSD #Psychedelics #Biotech https://prismmarketview.com/silo-pharmas-ptsd-program-aligns-with-federal-push-to-fast-track-psychedelic-therapies/
0 · Reply
Risktaking
Risktaking Apr. 29 at 2:20 PM
$SILO We only lack volume
0 · Reply
focafoca99
focafoca99 Apr. 29 at 2:03 PM
$SILO said its PTSD program is benefiting from a broader federal push to accelerate psychedelic therapies for mental health treatment.
0 · Reply
Risktaking
Risktaking Apr. 29 at 1:49 PM
$SILO What's the purpose of fake news if it doesn't spike?
0 · Reply
Jbjb90
Jbjb90 Apr. 29 at 1:40 PM
$SILO need actual news and more volume
0 · Reply
Supreme357
Supreme357 Apr. 29 at 1:39 PM
$SILO so fake news on the spike to get people to buy the crash the stock..wow!
0 · Reply
Trike
Trike Apr. 29 at 1:35 PM
$SILO that was it? We’re in hell.
0 · Reply
Risktaking
Risktaking Apr. 29 at 1:34 PM
$SAGT Out at $3. Brought my profits over to $SILO
0 · Reply
Jbjb90
Jbjb90 Apr. 29 at 1:19 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-s-ptsd-program-advances-as-fda-fast-tracks-psychedelic-79fglsxb8os8.html
0 · Reply